title: Immunovirotherapy for the treatment of glioblastoma.
abstract: We have recently described a new murine model of glioblastoma, generated by the implantation of syngeneic glioblastoma stem cells into immunocompetent mice, that recapitulates the salient histopathological and immunological features of the human disease. We employed this model to demonstrate the multifaceted activity of an oncolytic herpes simplex virus genetically modified to express interleukin-12, G47∆-IL12.
authors.affiliation: Brain Tumor Research Center; Department of Neurosurgery; Massachusetts General Hospital and Harvard Medical School; Boston, MA USA ; Momenta Pharmaceuticals; Cambridge, MA USA.
authors.forename: Tooba A
authors.initials: TA
authors.lastname: Cheema
authors.affiliation: Brain Tumor Research Center; Department of Neurosurgery; Massachusetts General Hospital and Harvard Medical School; Boston, MA USA.
authors.forename: Peter E
authors.initials: PE
authors.lastname: Fecci
authors.affiliation: Brain Tumor Research Center; Department of Neurosurgery; Massachusetts General Hospital and Harvard Medical School; Boston, MA USA.
authors.forename: Jianfang
authors.initials: J
authors.lastname: Ning
authors.affiliation: Brain Tumor Research Center; Department of Neurosurgery; Massachusetts General Hospital and Harvard Medical School; Boston, MA USA.
authors.forename: Samuel D
authors.initials: SD
authors.lastname: Rabkin
keywords: Treg; cancer stem cells; glioma; herpes simplex virus; interleukin-12; oncolytic virus